MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
-$1,049K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Fair value of vested restricted ...
    • Amortization of vendor advances
    • Amortization of intangible asset
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accounts payable and accrued exp...
    • Payment of deferred offering cos...
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Debt discount amortization
-
-
0
0
Fair value of common shares issued in connection with the conversion of accounts payable
-
-
0
0
Fair value of warrants issued in connection with convertible notes payable
-
-
0
0
Gain on settlement of accounts payable
-
-
0
-
Net loss
-1,388
-1,654
-1,365
-1,398
Vendor advances
-
-
0
0
Amortization of intangible asset
22
40
40
40
Amortization of vendor advances
213
220
212
660
Fair value of vested restricted stock units
259
259
259
70
Prepaid expenses and other current assets
-7
92
27
-64
Accounts payable and accrued expenses
-125
191
-203
-274
Proceeds from common stock issued for cash in connection with the closing of the initial public offering
-
-
0
0
Net cash used in operating activities
-1,012
-1,036
-1,084
-838
Proceeds from notes payable - officers
-
-
0
0
Proceeds from the at the market (atm) offering
7
385
-
-
Payment of deferred offering costs
44
165
0
0
Proceeds from the sale and exercise of prefunded warrants
-
-
0
0
Proceeds from the equity line of credit
-
-
0
3,379
Net increase in cash and cash equivalents
-
-
-1,084
-
Net cash provided by financing activities
-37
220
0
3,379
Net increase (decrease) in cash and cash equivalents
-1,049
-816
-1,084
2,541
Cash and cash equivalents, beginning of period
3,675
4,491
5,575
1,272
Cash and cash equivalents, end of period
2,626
3,675
4,491
5,575
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase(decrease) in cash and cash...-$1,049K (-159.53%↓ Y/Y)Fair value of vestedrestricted stock units$259K (69.28%↑ Y/Y)Amortization of vendoradvances$213K (-83.59%↓ Y/Y)Amortization of intangibleasset$22K (-72.50%↓ Y/Y)Prepaid expenses andother current assets-$7K (-114.00%↓ Y/Y)Proceeds from the at themarket (atm) offering$7K Net cash used inoperating activities-$1,012K (33.38%↑ Y/Y)Net cash provided byfinancing activities-$37K (-101.13%↓ Y/Y)Canceled cashflow$501K Canceled cashflow$7K Net loss-$1,388K (48.29%↑ Y/Y)Payment of deferredoffering costs$44K Accounts payable andaccrued expenses-$125K (60.44%↑ Y/Y)

Kairos Pharma, LTD. (KAPA)

Kairos Pharma, LTD. (KAPA)